CA2278220A1 - Use of .beta.3-adrenergic receptor agonists for the preparation of healing drugs - Google Patents
Use of .beta.3-adrenergic receptor agonists for the preparation of healing drugs Download PDFInfo
- Publication number
- CA2278220A1 CA2278220A1 CA002278220A CA2278220A CA2278220A1 CA 2278220 A1 CA2278220 A1 CA 2278220A1 CA 002278220 A CA002278220 A CA 002278220A CA 2278220 A CA2278220 A CA 2278220A CA 2278220 A1 CA2278220 A1 CA 2278220A1
- Authority
- CA
- Canada
- Prior art keywords
- groupe
- par
- alkyle
- est
- dessus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 230000035876 healing Effects 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- -1 benzylthio Chemical group 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 claims 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940082150 encore Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003415 peat Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZFLBZHXQAMUEFS-UHFFFAOYSA-N methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CC(C)NCC(O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- JLVSPVFPBBFMBE-HXSWCURESA-O sphingosylphosphocholine acid Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H]([NH3+])COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-O 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9700584 | 1997-01-21 | ||
| FR9700584A FR2758460B1 (fr) | 1997-01-21 | 1997-01-21 | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants |
| PCT/FR1998/000105 WO1998031357A1 (fr) | 1997-01-21 | 1998-01-21 | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2278220A1 true CA2278220A1 (en) | 1998-07-23 |
Family
ID=9502810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002278220A Abandoned CA2278220A1 (en) | 1997-01-21 | 1998-01-21 | Use of .beta.3-adrenergic receptor agonists for the preparation of healing drugs |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6235793B1 (pt) |
| EP (1) | EP0966276B1 (pt) |
| JP (1) | JP2001508790A (pt) |
| AR (1) | AR011546A1 (pt) |
| AT (1) | ATE255889T1 (pt) |
| AU (1) | AU5994198A (pt) |
| BR (1) | BR9807288A (pt) |
| CA (1) | CA2278220A1 (pt) |
| DE (1) | DE69820422T2 (pt) |
| FR (1) | FR2758460B1 (pt) |
| HR (1) | HRP980023A2 (pt) |
| NO (1) | NO326823B1 (pt) |
| UY (1) | UY24848A1 (pt) |
| WO (1) | WO1998031357A1 (pt) |
| ZA (1) | ZA98484B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2817257B1 (fr) | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
| JPWO2003106423A1 (ja) * | 2002-06-12 | 2005-10-13 | 住友製薬株式会社 | 環状アミン類およびそれを含む医薬組成物 |
| EP2100066B1 (en) * | 2006-12-22 | 2013-01-23 | National Oilwell Varco Denmark I/S | A flexible pipe |
| BRPI0720487B8 (pt) | 2006-12-22 | 2020-12-01 | Nat Oilwell Varco Denmark Is | tubo flexível |
| AU2022221588A1 (en) * | 2021-02-22 | 2023-09-07 | Northern Sydney Local Health District | Wound healing methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3070865D1 (en) * | 1979-11-15 | 1985-08-14 | Beecham Group Plc | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions |
| GB8528633D0 (en) * | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
| GB9308178D0 (en) * | 1993-04-21 | 1993-06-02 | Smithkline Beecham Plc | Novel compounds |
| US5578638A (en) * | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| JPH07228543A (ja) * | 1994-02-16 | 1995-08-29 | Fujisawa Pharmaceut Co Ltd | β３−アドレナリン作動薬の新規医薬用途 |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| US5512592A (en) * | 1994-09-09 | 1996-04-30 | Wake Forest University | Method of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine |
| US5597843A (en) | 1995-06-07 | 1997-01-28 | Houghten Pharmaceuticals | Use of a substituted 1,3-benzodioxole to reduce a wasting condition |
| US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
-
1997
- 1997-01-21 FR FR9700584A patent/FR2758460B1/fr not_active Expired - Fee Related
-
1998
- 1998-01-20 UY UY24848A patent/UY24848A1/es not_active Application Discontinuation
- 1998-01-20 HR HR9700584A patent/HRP980023A2/hr not_active Application Discontinuation
- 1998-01-20 AR ARP980100230A patent/AR011546A1/es unknown
- 1998-01-21 US US09/341,656 patent/US6235793B1/en not_active Expired - Fee Related
- 1998-01-21 AU AU59941/98A patent/AU5994198A/en not_active Abandoned
- 1998-01-21 DE DE69820422T patent/DE69820422T2/de not_active Expired - Fee Related
- 1998-01-21 WO PCT/FR1998/000105 patent/WO1998031357A1/fr active IP Right Grant
- 1998-01-21 CA CA002278220A patent/CA2278220A1/en not_active Abandoned
- 1998-01-21 JP JP53386198A patent/JP2001508790A/ja not_active Ceased
- 1998-01-21 BR BR9807288A patent/BR9807288A/pt not_active Application Discontinuation
- 1998-01-21 ZA ZA98484A patent/ZA98484B/xx unknown
- 1998-01-21 EP EP98903099A patent/EP0966276B1/fr not_active Expired - Lifetime
- 1998-01-21 AT AT98903099T patent/ATE255889T1/de not_active IP Right Cessation
-
1999
- 1999-07-20 NO NO19993548A patent/NO326823B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE255889T1 (de) | 2003-12-15 |
| DE69820422D1 (de) | 2004-01-22 |
| NO326823B1 (no) | 2009-02-23 |
| BR9807288A (pt) | 2000-03-21 |
| EP0966276A1 (fr) | 1999-12-29 |
| JP2001508790A (ja) | 2001-07-03 |
| AU5994198A (en) | 1998-08-07 |
| DE69820422T2 (de) | 2004-10-28 |
| AR011546A1 (es) | 2000-08-30 |
| ZA98484B (en) | 1998-07-30 |
| FR2758460A1 (fr) | 1998-07-24 |
| NO993548D0 (no) | 1999-07-20 |
| US6235793B1 (en) | 2001-05-22 |
| UY24848A1 (es) | 1998-04-21 |
| NO993548L (no) | 1999-07-20 |
| HRP980023A2 (en) | 1998-10-31 |
| WO1998031357A1 (fr) | 1998-07-23 |
| EP0966276B1 (fr) | 2003-12-10 |
| FR2758460B1 (fr) | 1999-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0385846B1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
| CA2278661A1 (en) | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour reguler l'appetance | |
| EP0939626B1 (fr) | Forme galenique a liberation prolongee de milnacipran | |
| US6187820B1 (en) | Medical treatment to improve lipid levels | |
| EP1998778B1 (fr) | Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques | |
| NZ528302A (en) | Pharmaceutical salts of pharmaceutically active compounds and sugar substitutes | |
| EP3185859B1 (en) | New therapeutic approaches for treating parkinson's disease | |
| CA2451569A1 (en) | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | |
| HU207441B (en) | Method for producing therapeutical preparation applicable for systematic feeding through the skin containing deprenyl as active ingredient | |
| JP2001527514A (ja) | 交感神経作用アミン塩のための変質剤 | |
| US10010515B2 (en) | Therapeutic approaches for treating Parkinson's disease | |
| CA2278220A1 (en) | Use of .beta.3-adrenergic receptor agonists for the preparation of healing drugs | |
| EP2240505B1 (fr) | Peptide activateur de la synthese des aquaporines | |
| FR2690847A1 (fr) | Compositions à activité agoniste des récepteurs analogues à 5HT1 sélective. | |
| WO2006087363A1 (fr) | Utilisation cosmétique d'au moins un tétrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent pour ralentir la chute des cheveux et/ou stimuler leur croissance | |
| CA2442691A1 (en) | Enteric ketoacid salts and amino acids and their use for preparing medicines | |
| CH675356A5 (pt) | ||
| CA2365500A1 (fr) | Association d'inhibiteur(s) de no synthase et d'antioxydant(s) metabolique(s) | |
| FR2489146A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
| CA2376302A1 (fr) | Composition pharmaceutique comprenant du no ou au moins un compose donneur de no ou encore un compose capable de liberer ou d'induire la formation de no dans les cellules | |
| EP1121108B1 (fr) | Nouvelle utilisation therapeutique de composes a activite beta-3-agoniste | |
| WO1988007363A1 (fr) | Composition pour le traitement de l'epiderme | |
| WO2023175010A1 (fr) | Utilisation du bazedoxifene pour augmenter la survie musculaire | |
| WO2009019385A1 (fr) | Utilisation de l'éflucimibe pour la préparation d'un médicament destiné à prévenir ou à traiter une maladie due à dysfonctionnement des glandes sébacées chez l'homme ou l'animal | |
| FR2753375A1 (fr) | Utilisation dans une composition cosmetique ou pour la preparation d'un medicament d'au moins un inhibiteur de sulfotransferases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |